Initially there initially there initially there initially there initially there initially there initially there initially initially initially initially initially initially initially initially initially there initially there was no specific way to reverse the anticoagulant effect of dabigatran in in in in in in in in in the you know um so so I mean so um um event of of of of of of of of of a major bleeding event, unlike for warfarin, but a dabigatran antidote (idarucizumab) was approved by the FDA in 2015.